CHRU De Nancy
Verified site
Vandoeuvre Les Nancy, France
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
Tinea capitis is a common fungal infection of the scalp that causes itchy, scaly patches and sometimes hair loss in children. The study examines two oral doses of the antifungal medicine terbinafine: a higher dose of 500 mg taken once daily and a standard dose of 250 mg taken once daily. Both doses are given by mouth and are intended to clear the infection from the scalp and hair.
The purpose of the study is to compare how well the high dose works compared with the standard dose in achieving a clinical cure, meaning the scalp looks clear or almost clear, together with a negative mycological culture, a laboratory test that shows no fungus present, after four weeks of treatment. Children will receive the assigned medication for several weeks and will be examined by a doctor at weeks 2, 4, and 8. During these visits the doctor will look at how the scalp looks, check the laboratory test results, and score any remaining signs using the Total Signs and Symptoms Score, a simple number that reflects how many symptoms are still present. Hair regrowth in areas that had lost hair will also be noted. The study follows participants for a short period to see if the improvement is maintained.
The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.
6 criteria
11 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Vandoeuvre Les Nancy, France
Marseille, France
Paris, France
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an oral medication given at a higher amount in this study. It is being tested to see if taking more of the medicine helps children with scalp ringworm (tinea capitis) heal faster and completely, with no fungus left in lab tests after four weeks.
is also given at the usual amount that doctors normally prescribe. This standard dose serves as the comparison group, helping researchers understand whether the higher amount provides any extra benefit over the regular treatment.
This medication is taken by mouth as a daily tablet of 500 mg; it is an approved antifungal used to treat fungal infections of the scalp, especially tinea capitis in children. It works by blocking an enzyme that the fungus needs to build its cell wall, which stops the fungus from growing and eventually kills it. Terbinafine belongs to the allylamine class of antifungal drugs and is well described in medical literature. It is commonly prescribed for skin and nail fungal infections.
This medication is taken by mouth as a daily tablet of 250 mg; it is the standard dose of an approved antifungal used for treating scalp ringworm in children. It acts by inhibiting the fungal enzyme that makes the cell wall, preventing the fungus from multiplying. Terbinafine is classified as an allylamine antifungal and has a long history of use in medical practice. It is widely used for various skin and nail fungal infections.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.